Yale Cancer Center
at Smilow Cancer Hospital
Yale Cancer Center is Connecticut's only cancer center designated as a Comprehensive Cancer Center by the National Cancer Institute—and one of only 57 in the nation. The significance of this designation has profound implications for those who choose Smilow Cancer Hospital as the place where they will be cared for and receive treatment for their cancer. National Cancer Institute cancer centers are national leaders in cancer research, prevention, detection, and treatment. This provides patients at Smilow Cancer Hospital with novel treatment options and expert care.
News
Showing 3 of 7
Fact Sheets
Showing 4 of 17
Centerpoint
Showing 3 of 57
News from Yale Cancer Center
Showing 3 of 1353
Cancer Clinical Trials
Showing 2 of 293
- Phase 1 Cancers
Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 in Adult Subjects With Advanced Solid Tumors
- Breast Cancer
2000033529: A pilot study to evaluate biomarkers and safety of dapagliflozin concomitant with neoadjuvant therapy for patient with HER2-negative early-stage breast cancer and hyperinsulinemia (previously HIC 2000031461) [Yale HIC]